Net product sales at pharmaceutical giant Celgene Corp. climbed to $1.56 billion in the second quarter of 2013, a 17 percent increase over the same period last year, according to the company's most recent earnings report.
In that same time, adjusted net income at the Summit-based company rose 20 percent, to $653 million. Total revenue also was up for the quarter, climbing to $1.59 billion, from $1.36 billion last year.
Celgene specializes in developing drugs to treat cancer and inflammatory diseases.
Reporter Mary Johnson is @mjohns422 on Twitter.